Tafenoquine plus Artesunate-pyronaridine — Competitive Intelligence Brief

Tafenoquine plus Artesunate-pyronaridine (Tafenoquine plus Artesunate-pyronaridine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium falciparum and Plasmodium vivax (parasite species); mechanism involves multiple targets including mitochondrial function and heme detoxification Infectious Disease Small molecule

Target snapshot

Tafenoquine plus Artesunate-pyronaridine (Tafenoquine plus Artesunate-pyronaridine) — Menzies School of Health Research. This combination targets malaria parasites through two complementary mechanisms: tafenoquine eliminates dormant liver-stage parasites and gametocytes, while artesunate-pyronaridine rapidly kills blood-stage parasites.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tafenoquine plus Artesunate-pyronaridine TARGET	Tafenoquine plus Artesunate-pyronaridine	Menzies School of Health Research	marketed	Antimalarial combination	Plasmodium falciparum and Plasmodium vivax (parasite species); mechanism involves multiple targets including mitochondrial function and heme detoxification
Artesunate-amodiaquine fixed-dose combination	Artesunate-amodiaquine fixed-dose combination	Epicentre	marketed	Antimalarial combination	Plasmodium falciparum (multiple parasite targets)
Mefloquine and Dihydroartemisinin-piperaquine	Mefloquine and Dihydroartemisinin-piperaquine	University of Oxford	marketed	Antimalarial combination	Parasite heme polymerase (mefloquine); parasite proteins and lipids (dihydroartemisinin); hemozoin (piperaquine)
Atovaquone / Proguanil	Atovaquone / Proguanil	Radboud University Medical Center	marketed	Antimalarial combination	Mitochondrial electron transport chain (atovaquone); dihydrofolate reductase (proguanil)
Tafenoquine plus DHA-Piperaquine	Tafenoquine plus DHA-Piperaquine	Menzies School of Health Research	marketed	Antimalarial combination	Plasmodium hypnozoites (tafenoquine); Plasmodium blood-stage parasites (DHA-piperaquine)
artesunate-amodiaquine (AS-AQ)	artesunate-amodiaquine (AS-AQ)	Yale University	marketed	Artemisinin derivative + aminoquinoline antimalarial combination	Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase
Atovaquone Proguanil and Artesunate Pyronaridine	Atovaquone Proguanil and Artesunate Pyronaridine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium mitochondrial electron transport chain, dihydrofolate reductase, heme polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class